[5] de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023. 401(10378): 733-746. [6] Rosell R, Codony-Servat J, Nieto JG, et a...
Cell lines with a KRAS (V12) mutation and KRAS gains or loss (n=7) are 10 times more resistant than those having neither a KRAS (V12) mutation nor KRAS CNV (n=14). Significant differences in baseline and MEK162-induced gene expression exist between the sensitive and resistant lines, ...
12. Sacher A, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023 Aug 24;389(8):710-721. 13. Amodio V, et al. EGFR Blockade Reverts Resistance to...
[3]Wouter W. Mellema, et al.Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.Lung Cancer. 2015 Nov;90(2):249-54. [4]Anna Ketal.Survival outcome according to KRAS mutation status in newly diagnos...
Ntai I, Fornelli L, DeHart C J, et al. Precise characterization ofKRAS4B proteoforms in human colorectal cells and tumors revealsmutation/modification cross-talk[J]. Proc Natl Acad Sci USA, 2018,115(16): 4140-4145. Ryan M B, ...
Lung adenocarcinomas and large cell carcinomas did not show codon 146 mutations. We did, however, identify a KRAS A146 mutation in the ML-2 acute myeloid leukemia cell line and an NRAS A146 mutation in the NALM-6 B-cell acute lymphoblastic leukemia line, suggesting that the contribution of...
1.Johnson ML, et al. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. ESMO Congress 2022, LBA10 2.Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed...
Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but how oncogenic mutations impact these interactions and their functions at a network-level scale is poorly understood. Here, we analyze how a common oncogenic KRAS mutation (KRASG13D) affects PPIN structure and ...
ed that different type of KRAS mutation s result in different biology characte rs.Unlike KRAS codon 1 2 mutational sta tus.metastatic colorectal cancer with KRASG1 3D mutations benefit from the tr eatment with cetuximab.T11iS result ne
Both tumor cell populations were treated with a combination of mAb and chemotherapy drugs. It was observed that even the minimal initial concentration of KRAS mutation before the treatment has the ability to make the tumor refractory to the treatment. Patient's immune responses are specifically ...